Reproductive Endocrinology Associates of Charlotte Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2014
NCT02119117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Endocrinology Associates, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

insulin glargine (toujeo) (2 trials)

Drugs in Other Trials (1)

ubiquinone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2